Latest news with #AutolusTherapeutics
Yahoo
15 hours ago
- Automotive
- Yahoo
Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) on June 12, keeping the price target at $10.00. The analyst cited the promising results of the FELIX study for obe-cel in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) as one of the factors supporting the optimistic rating, stating that the updated analysis highlights a notable number of patients in remission with no need for further therapy. This is a positive indicator, according to the analyst, especially in comparison to other treatments such as Tecartus. A laboratory technician carefully studying a microscope with a biopharmaceutical product inside. While the analyst acknowledged that 38% of responders were still in remission with a median follow-up of 33 months, a slight drop from the 40% reported at 21.5 months, he stated that the results are still impressive. He also cited other promising factors, including the overall survival and event-free survival rates, as well as the absence of new safety concerns. According to Blum, these factors suggest a positive reception from physicians and the potential for higher commercial adoption of obe-cel, supporting the optimistic outlook for Autolus Therapeutics plc (NASDAQ:AUTL). Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer, with a focus on chimeric antigen receptor (CAR) T cell therapy. The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies. While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
2 days ago
- Automotive
- Yahoo
Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) on June 12, keeping the price target at $10.00. The analyst cited the promising results of the FELIX study for obe-cel in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) as one of the factors supporting the optimistic rating, stating that the updated analysis highlights a notable number of patients in remission with no need for further therapy. This is a positive indicator, according to the analyst, especially in comparison to other treatments such as Tecartus. A laboratory technician carefully studying a microscope with a biopharmaceutical product inside. While the analyst acknowledged that 38% of responders were still in remission with a median follow-up of 33 months, a slight drop from the 40% reported at 21.5 months, he stated that the results are still impressive. He also cited other promising factors, including the overall survival and event-free survival rates, as well as the absence of new safety concerns. According to Blum, these factors suggest a positive reception from physicians and the potential for higher commercial adoption of obe-cel, supporting the optimistic outlook for Autolus Therapeutics plc (NASDAQ:AUTL). Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer, with a focus on chimeric antigen receptor (CAR) T cell therapy. The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies. While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
02-04-2025
- Automotive
- Yahoo
Autolus Therapeutics price target lowered to $10 from $11 at Truist
Truist lowered the firm's price target on Autolus Therapeutics (AUTL) to $10 from $11 and keeps a Buy rating on the shares. The firm is updating its model and estimates for Autolus, slightly lowering our price target as it removes AUTO4 from its valuation, the analyst tells investors in a research note. Truist adds it is assigning no value to autoimmune indications, but this could change following Autolus' April R&D day. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on AUTL: Disclaimer & DisclosureReport an Issue Autolus Therapeutics: Positive Momentum Amid Financial Challenges Autolus Therapeutics price target lowered to $6 from $8 at Wells Fargo Positive Outlook and Buy Rating for Autolus Therapeutics Driven by Strategic Developments and Promising Prospects Autolus Therapeutics Reports Strong 2024 Results Optimistic Buy Rating for Autolus Therapeutics Driven by Strategic Advancements and Successful Launch of Aucatzyl Sign in to access your portfolio
